China CRO Pharmaron Buys Quotient Bioresearch of the UK

Pharmaron, a Beijing CRO/CMO, acquired Quotient Bioresearch of the UK. Quotient focuses on integrating radiochemistry and metabolism, an expertise derived from its purchase of GE Amersham's radiosynthesis business in 2009. Pharmaron said the transaction, besides adding the radiochemistry technology, would broaden its footprint, increasing market access in Asia, Europe and the US. The price was not disclosed. More details.... Share this with colleagues: // //